Global Information
회사소개 | 문의 | 비교리스트

간내 담관암(ICCA) : 시장 인사이트, 역학, 시장 예측(2030년)

Intrahepatic Cholangiocarcinoma (ICCA) - Market Insights, Epidemiology, and Market Forecast - 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 11월 상품 코드 968235
페이지 정보 영문 241 Pages
가격
US $ 6,950 ₩ 7,768,000 PDF (Single User License)
US $ 13,900 ₩ 15,536,000 PDF (Site License)
US $ 20,850 ₩ 23,304,000 PDF (Global License)


간내 담관암(ICCA) : 시장 인사이트, 역학, 시장 예측(2030년) Intrahepatic Cholangiocarcinoma (ICCA) - Market Insights, Epidemiology, and Market Forecast - 2030
발행일 : 2020년 11월 페이지 정보 : 영문 241 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

간세포암에 연발하는 간의 원발성 악성 신생물인 간내 담관암(ICCA)은 간내 담관 상피(상피 및 담관 주위선의 내층)로부터 발생하고, 담관 세포의 다양한 분화를 나타냅니다. 악성 종양은 담관 상피의 몇 개 부분, 종말관(헤링의 관)부터 바터 팽대부까지 몇 개 부분 및 담관 주위선(벽내 및 벽외)으로부터 발생할 가능성이 있습니다.

미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본 주요 7개국의 간내 담관암(Intrahepatic Cholangiocarcinoma) 역학과 관련 시장에 대해 조사한 것으로, 시장 개요, 질병 배경과 개요, 역학과 환자수, 각국의 역학, 치료법, 미충족 수요, 출시된 의약품, 새로운 치료제, 국가별 분석과 시장 규모, 성장 촉진요인과 장벽 등의 정보를 제공합니다.

목차

제1장 주요 조사 결과

제2장 주요 요약

제3장 시장 개요

제4장 질환 배경과 개요

  • 서론
  • 증상
  • 전통적인 분류법과 새로운 분류법
  • 분자 병태
  • 진단
    • 진단을 위한 알고리즘
    • 병기 분류

제5장 환자 여정

제6장 역학과 환자수

  • 주요 조사 결과
  • 역학 조사 방법
  • 주요 7개국의 총증례수

제7장 미국의 역학

  • 가정과 근거
  • 신규 증례수
  • 성별 신규 증례수
  • 연령별 신규 증례수
  • 병기별 신규 증례수
  • 바이오마커별 신규 증례수

제8장 유럽 5개국의 역학

  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국

제9장 일본의 역학

제10장 치료

  • 치료 알고리즘
  • 치료를 위한 가이드라인

제11장 미충족 수요

제12장 출시된 의약품

  • Pemazyre(Pemigatinib) : Incyte Corporation
    • 개요
    • 규제 마일스톤
    • 기타 개발 활동
    • 장점과 단점
    • 임상 개발
    • 안전성과 유효성
    • 제품 프로파일
  • Rozlytrek(Entrectinib) : Roche
    • 개요

제13장 새로운 치료제

  • 주요 경쟁 제품
  • Melphalan/HDS: Delcath Systems
    • 개요
    • 기타 개발 활동
    • 임상 개발
    • 안전성과 유효성
    • 제품 프로파일
  • Derazantinib: Basilea Pharmaceutica
  • Ivosidenib: Agios Pharmaceuticals
    • 개요
  • Regorafenib: Bayer
  • Larotrectinib: Loxo Oncology/Bayer
  • Infigratinib: QED Therapeutics
  • Balversa(Erdafitinib): Janssen Pharmaceutical
  • Futibatinib(TAS-120): Taiho Oncology
  • Opaganib(ABC294640; Yeliva): RedHill Biopharma
  • Niraparib(Zejula): GlaxoSmithKline
  • Bintrafusp alfa(GSK4045154; M7824): Merck/GlaxoSmithKline
  • E7090: Eisai
  • Lonsurf(Trifluridine and Tipiracil Hydrochloride/TAS-102): Taiho
  • Pharmaceutical/Servier
  • Copanlisib(BAY 80-6946): Bayer
  • STI-3031(IMC-001): Sorrento Therapeutics/Yuhan Corporation
  • HMPL-453: Hutchison Medipharma
  • Famitinib: Jiangsu HengRui Medicine
  • Durvalumab: AstraZeneca
  • Abemaciclib: Eli Lilly
  • Nal-IRI with 5-fluorouracil and/or Leucovorin: Servier Laboratories
  • GNS561: Genoscience Pharma
  • Olutasidenib(FT-2102): Forma Therapeutics
  • Gemcitabine, Cisplatin, and MEK162: Array BioPharma

제14장 주요 7개국 시장 분석

  • 주요 조사 결과
  • 시장 조사 방법
  • 속성 분석
    • 단계 III 약
    • 단계 II 약
  • 주요 7개국 시장 규모
  • 주요 7개국 시장 전망

제15장 새로운 치료법의 가능성

제16장 시장 예측의 주요 가정

제17장 미국의 시장 규모

  • 시장 규모
  • 치료법별 시장 규모

제18장 유럽 5개국의 시장 규모

  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국

제19장 일본의 시장 규모

제20장 시장 성장 촉진요인

제21장 시장 장벽

제22장 SWOT 분석

제23장 상환과 시장 진출

제24장 공인 단체

제25장 부록

제26장 DelveInsight 서비스

제27장 면책사항

제28장 DelveInsight 소개

KSM 20.11.18

List of Tables

  • Table 1 Summary of Intrahepatic Cholangiocarcinoma (ICCA), Market, Epidemiology, and Key Events (2017-2030)
  • Table 2 Gross features of intrahepatic cholangiocarcinoma
  • Table 3 Classification of ICCA
  • Table 4 Molecular alterations in ICCA
  • Table 5 TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
  • Table 6 AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
  • Table 7 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the 7MM (2017-2030)
  • Table 8 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the US (2017-2030)
  • Table 9 Gender-specific Incident Cases of ICCA in the US (2017-2030)
  • Table 10 Age-specific Incident Cases of ICCA in the US (2017-2030)
  • Table 11 Stage-specific Incident Cases of Intrahepatic CCA in the US (2017-2030)
  • Table 12 Biomarker-specific Incident Cases of ICCA in the US (2017-2030)
  • Table 13 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Germany (2017-2030)
  • Table 14 Gender-Specific Incident Cases of ICCA in Germany (2017-2030)
  • Table 15 Age-specific Incident Cases of ICCA in Germany (2017-2030)
  • Table 16 Stage-specific Incident Cases of Intrahepatic CCA in Germany (2017-2030)
  • Table 17 Biomarker-specific Incident Cases of ICCA in Germany (2017-2030)
  • Table 18 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in France (2017-2030)
  • Table 19 Gender-specific Incident Cases of ICCA in France (2017-2030)
  • Table 20 Age-specific Incident Cases of ICCA in France (2017-2030)
  • Table 21 Stage-specific Incident Cases of Intrahepatic CCA in France (2017-2030)
  • Table 22 Biomarker-specific Incident Cases of ICCA in France (2017-2030)
  • Table 23 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Italy (2017-2030)
  • Table 24 Gender-specific Incident Cases of ICCA in Italy (2017-2030)
  • Table 25 Age-specific Incident Cases of ICCA in Italy (2017-2030)
  • Table 26 Stage-specific Incident Cases of Intrahepatic CCA in Italy (2017-2030)
  • Table 27 Biomarker-specific Incident Cases of ICCA in Italy (2017-2030)
  • Table 28 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Spain (2017-2030)
  • Table 29 Gender-specific Incident Cases of ICCA in Spain (2017-2030)
  • Table 30 Age-specific Incident Cases of ICCA in Spain (2017-2030)
  • Table 31 Stage-specific Incident Cases of Intrahepatic CCA in Spain (2017-2030)
  • Table 32 Biomarker-specific Incident Cases of ICCA in Spain (2017-2030)
  • Table 33 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the UK (2017-2030)
  • Table 34 Gender-specific Incident Cases of CCA in the UK (2017-2030)
  • Table 35 Age-specific Incident Cases of ICCA in the UK (2017-2030)
  • Table 36 Stage-specific Incident Cases of Intrahepatic CCA in the UK (2017-2030)
  • Table 37 Biomarker-specific Incident Cases of ICCA in the UK (2017-2030)
  • Table 38 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Japan (2017-2030)
  • Table 39 Gender-specific Incident Cases of ICCA in Japan (2017-2030)
  • Table 40 Age-specific Incident Cases of ICCA in Japan (2017-2030)
  • Table 41 Stage-specific Incident Cases of Intrahepatic CCA in Japan (2017-2030)
  • Table 42 Biomarker-specific Incident Cases of ICCA in Japan (2017-2030)
  • Table 43 Recommendations of Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and management
  • Table 44 Pemigatinib, Clinical Trial Description, 2020
  • Table 45 Entrectinib, Clinical Trial Description, 2020
  • Table 46 Comparison of emerging drugs under development
  • Table 47 Comparison of emerging drugs under development (Continued)
  • Table 48 Comparison of emerging drugs under development (Continued)
  • Table 49 Comparison of emerging drugs under development (Continued)
  • Table 50 Melphalan/HDS, Clinical Trial Description, 2020
  • Table 51 Derazantinib, Clinical Trial Description, 2020
  • Table 52 AG-120, Clinical Trial Description, 2020
  • Table 53 Regorafenib, Clinical Trial Description, 2020
  • Table 54 Larotrectinib, Clinical Trial Description, 2020
  • Table 55 Infigratinib, Clinical Trial Description, 2020
  • Table 56 Erdafitinib, Clinical Trial Description, 2020
  • Table 57 Futibatinib Clinical Trial Description, 2020
  • Table 58 Opaganib Clinical Trial Description, 2020
  • Table 59 Niraparib Clinical Trial Description, 2020
  • Table 60 Bintrafusp alfa Clinical Trial Description, 2020
  • Table 61 E7090, Clinical Trial Description, 2020
  • Table 62 Lonsurf, Clinical Trial Description, 2020
  • Table 63 Copanlisib (BAY 80-6946), Clinical Trial Description, 2020
  • Table 64 STI-3031 (IMC-001), Clinical Trial Description, 2020
  • Table 65 HMPL-453, Clinical Trial Description, 2020
  • Table 66 Famitinib, Clinical Trial Description, 2020
  • Table 67 Durvalumab, Clinical Trial Description, 2020
  • Table 68 Abemaciclib, Clinical Trial Description, 2020
  • Table 69 Nal-IRI with 5-fluorouracil and/or Leucovorin, Clinical Trial Description, 2020
  • Table 70 GNS561, Clinical Trial Description, 2020
  • Table 71 Olutasidenib (FT-2102), Clinical Trial Description, 2020
  • Table 72 Gemcitabine, Cisplatin and MEK162, Clinical Trial Description, 2020
  • Table 73 Market Size of ICCA in the 7MM in USD Million (2017-2030)
  • Table 74 Market Size of ICCA by therapies in the 7MM, in USD Million (2017-2030)
  • Table 75 Key market forecast assumptions for Melphalan/HDS
  • Table 76 Key market forecast assumptions for Ivosidenib (AG-120)
  • Table 77 Key market forecast assumptions for Infigratinib
  • Table 78 Key market forecast assumptions for Futibatinib (TAS-120)
  • Table 79 Key market forecast assumptions for Bintrafusp alfa
  • Table 80 Key market forecast assumptions for Derazantinib
  • Table 81 Key market forecast assumptions for E7090
  • Table 82 Key market forecast assumptions for Larotrectinib
  • Table 83 Key market forecast assumptions for Copanlisib (BAY 80-6946)
  • Table 84 Key market forecast assumptions for Regorafenib
  • Table 85 The US Market Size of ICCA in USD Million (2017-2030)
  • Table 86 Market Size of ICCA by therapies in the US, in USD Million (2017-2030)
  • Table 87 Germany Market Size of ICCA in USD Million (2017-2030)
  • Table 88 Market Size of ICCA by therapies in Germany, in USD Million (2017-2030)
  • Table 89 France Market Size of ICCA in USD Million (2017-2030)
  • Table 90 Market Size of ICCA by therapies in France, in USD Million (2017-2030)
  • Table 91 Italy Market Size of ICCA in USD Million (2017-2030)
  • Table 92 Market Size of ICCA by therapies in Italy, in USD Million (2017-2030)
  • Table 93 Spain Market Size of ICCA in USD Million (2017-2030)
  • Table 94 Market Size of ICCA by therapies in Spain, in USD Million (2017-2030)
  • Table 95 UK Market Size of Intrahepatic Cholangiocarcinoma (ICCA) in USD Million (2017-2030)
  • Table 96 Market Size of ICCA by therapies in the UK, in USD Million (2017-2030)
  • Table 97 Japan Market Size of ICCA in USD Million (2017-2030)
  • Table 98 Market Size of ICCA by therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1 Cholangiocarcinoma
  • Figure 2 Cholangiocarcinoma - anatomical classification
  • Figure 3 Gross features of intrahepatic cholangiocarcinoma
  • Figure 4 Symptoms of ICCA
  • Figure 5 Summary of key molecular alterations involved in ICCA carcinogenesis
  • Figure 6 Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
  • Figure 7 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the 7MM (2017-2030)
  • Figure 8 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the US (2017-2030)
  • Figure 9 Gender-specific Incident Cases of ICCA in the US (2017-2030)
  • Figure 10 Age-specific Incident Cases of ICCA in the US (2017-2030)
  • Figure 11 Stage-specific Incident Cases of Intrahepatic CCA in the US (2017-2030)
  • Figure 12 Biomarker-specific Incident Cases of ICCA in the US (2017-2030)
  • Figure 13 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Germany (2017-2030)
  • Figure 14 Gender-specific Incident Cases of ICCA in Germany (2017-2030)
  • Figure 15 Age-specific Incident Cases of ICCA in Germany (2017-2030)
  • Figure 16 Stage-specific Incident Cases of Intrahepatic CCA in Germany (2017-2030)
  • Figure 17 Biomarker-specific Incident Cases of ICCA in Germany (2017-2030)
  • Figure 18 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in France (2017-2030)
  • Figure 19 Gender-specific Incident Cases of ICCA in France (2017-2030)
  • Figure 20 Age-specific Incident Cases of ICCA in France (2017-2030)
  • Figure 21 Stage-specific Incident Cases of Intrahepatic ICCA in France (2017-2030)
  • Figure 22 Biomarker-specific Incident Cases of ICCA in France (2017-2030)
  • Figure 23 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Italy (2017-2030)
  • Figure 24 Gender-specific Incident Cases of ICCA in Italy (2017-2030)
  • Figure 25 Age-specific Incident Cases of ICCA in Italy (2017-2030)
  • Figure 26 Stage-specific Incident Cases of Intrahepatic CCA in Italy (2017-2030)
  • Figure 27 Biomarker-specific Incident Cases of ICCA in Italy (2017-2030)
  • Figure 28 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Spain (2017-2030)
  • Figure 29 Gender-specific Incident Cases of ICCA in Spain (2017-2030)
  • Figure 30 Age-specific Incident Cases of ICCA in Spain (2017-2030)
  • Figure 31 Stage-specific Incident Cases of Intrahepatic CCA in Spain (2017-2030)
  • Figure 32 Biomarker-specific Incident Cases of ICCA in Spain (2017-2030)
  • Figure 33 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the UK (2017-2030)
  • Figure 34 Gender-specific Incident Cases of CCA in the UK (2017-2030)
  • Figure 35 Age-specific Incident Cases of ICCA in the UK (2017-2030)
  • Figure 36 Stage-specific Incident Cases of Intrahepatic CCA in the UK (2017-2030)
  • Figure 37 Biomarker-specific Incident Cases of ICCA in the UK (2017-2030)
  • Figure 38 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Japan (2017-2030)
  • Figure 39 Gender-specific Incident Cases of ICCA in Japan (2017-2030)
  • Figure 40 Age-specific Incident Cases of ICCA in Japan (2017-2030)
  • Figure 41 Stage-specific Incident Cases of Intrahepatic CCA in Japan (2017-2030)
  • Figure 42 Biomarker-specific Incident Cases of ICCA in Japan (2017-2030)
  • Figure 43 Basic Treatment Division
  • Figure 44 Signaling pathways involved in intrahepatic cholangiocarcinoma and the corresponding molecular therapies
  • Figure 45 An approach to the management of ICCA involves an initial assessment of its resectability
  • Figure 46 A suggested treatment algorithm for patients with ICCA
  • Figure 47 Unmet Needs of Intrahepatic cholangiocarcinoma (ICCA)
  • Figure 48 Market Size of ICCA in the 7MM in USD Million (2017-2030)
  • Figure 49 Market Size of ICCA by therapies in the 7MM in USD Million (2017-2030)
  • Figure 50 Market Size of ICCA in the US, USD Millions (2017-2030)
  • Figure 51 Market Size of ICCA by Therapies in the US in USD Million (2017-2030)
  • Figure 52 Market Size of ICCA in Germany, USD Millions (2017-2030)
  • Figure 53 Market Size of ICCA by Therapies in Germany in USD Million (2017-2030)
  • Figure 54 Market Size of ICCA in France, USD Millions (2017-2030)
  • Figure 55 Market Size of ICCA by Therapies in France in USD Million (2017-2030)
  • Figure 56 Market Size of ICCA in Italy, USD Millions (2017-2030)
  • Figure 57 Market Size of ICCA by Therapies in Italy in USD Million (2017-2030)
  • Figure 58 Market Size of ICCA in Spain, USD Millions (2017-2030)
  • Figure 59 Market Size of ICCA by Therapies in Spain in USD Million (2017-2030)
  • Figure 60 Market Size of ICCA in the UK, USD Millions (2017-2030)
  • Figure 61 Market Size of ICCA by Therapies in the UK in USD Million (2017-2030)
  • Figure 62 Market Size of ICCA in Japan, USD Millions (2017-2030)
  • Figure 63 Market Size of ICCA by Therapies in Japan in USD Million (2017-2030)
  • Figure 64 Market Drivers
  • Figure 65 Market Barriers
  • Figure 66 SWOT Analysis of Intrahepatic cholangiocarcinoma (ICCA)

DelveInsight's 'Intrahepatic Cholangiocarcinoma (ICCA)-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the ICCA, historical and forecasted epidemiology as well as the ICCA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The ICCA market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM ICCA market size from 2017 to 2030. The Report also covers current ICCA treatment practice/algorithm, market drivers, market barriers, unmet medical needs, SWOT analysis to curate the best of the opportunities, and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Intrahepatic Cholangiocarcinoma (ICCA) Disease Understanding and Treatment Algorithm

Intrahepatic Cholangiocarcinoma (ICCA) Overview

Intrahepatic cholangiocarcinoma (ICCA), a primary malignant neoplasm of the liver secondary to hepatocellular carcinoma, arises from intrahepatic biliary epithelium (lining epithelia and peribiliary glands) and shows a variable cholangiocytic differentiation. The malignant tumor may arise from any portion of the bile duct epithelium, i.e., anywhere from the terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural).

Based on the macroscopic tumor growth pattern ICCA can be classified as mass-forming type, periductal infiltrating type, or intraductal growing type according to the classification of the Liver Cancer Study Group of Japan. It can also be classified into two types according to the site of involvement and histologic features: perihilar large duct ICCA, which involves the intrahepatic large bile ducts, and peripheral small duct ICCA, which involves the intrahepatic small bile ducts

Intrahepatic Cholangiocarcinoma (ICCA) Diagnosis

In most of the cases, ICCAs are diagnosed incidentally and patients usually become symptomatic at advanced stage disease with unspecific symptoms such as abdominal pain, malaise, night sweats, and cachexia. The most commonly used tumor marker for CCA is carbohydrate antigen 19-9 (CA 19-9). There are various tests to confirm the diagnosis. These include biopsy, blood tests, and dynamic cross-sectional imaging.

Continued in the report…..

Intrahepatic Cholangiocarcinoma (ICCA) Treatment

Very few nonsurgical treatment options are available for ICCA. The standard treatment includes surgery, radiation therapy, and chemotherapy. New clinical approaches are also being evaluated including liver transplant, targeted therapies, and immunotherapies.

As per the NCCN guidelines, the adjuvant treatment for indication include adjuvant capecitabine, gemcitabine monotherapy or combined with cisplatin or capecitabine, capecitabine monotherapy or combined with cisplatin or oxaliplatin, and 5-fluorouracil monotherapy or combined with cisplatin or oxaliplatin. Additionally, treatment options for advanced BTCs include enrollment in the clinical trial, systemic therapies (gemcitabine or fluoropyrimidine-based chemotherapy, or pembrolizumab for patients with MSI-H/dMMR tumors), fluoropyrimidine-based chemoradiation, and radiotherapy without additional chemotherapy.

Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of ICCA, Gender-specific Incident Cases of ICCA, Age-specific Incident Cases of ICCA, Stage-specific Incident Cases of ICCA, and Biomarker-specific Incident Cases of ICCA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Key Findings

  • In 2017, a total of 10,177 patients were affected with ICCA in the 7MM.
  • The United States contributes the largest share with 3,639 incident cases in 2017, acquiring near about 35.76% of the totals 7MM share. On the other hand, EU5 and Japan will account for 37.40% and 26.84% population share, respectively, by 2017.
  • ICCA is slightly common in males as compared to females.

Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology

The epidemiology segment also provides the ICCA epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Intrahepatic Cholangiocarcinoma (ICCA) Drug Chapters

The drug chapter segment of the ICCA report encloses the detailed analysis of ICCA current therapies, mid-phase, and late-stage pipeline drugs. It also helps to understand the ICCA clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug, and the latest news and press releases.

Intrahepatic Cholangiocarcinoma (ICCA) Marketed Drugs

Pemazyre (Pemigatinib): Incyte Corporation

Pemazyre (pemigatinib, INCB054828) is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. It is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangements as detected by an FDA-approved test.

Incyte Corporation is developing pemigatinib in various other indications such as bladder cancer, solid tumors, and 8p11 myeloproliferative neoplasms. It is approved in the US to treat adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangements detected by an FDA-approved test. Also, the marketing authorization application (MAA) seeking the approval of pemigatinib for patients with cholangiocarcinoma in the EU has been validated by the European Medicines Agency (EMA). It is currently under review for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy. In September 2020, US biotech Incyte filed a new drug application (NDA) in Japan for its cholangiocarcinoma treatment pemigatinib, also known by its trade name Pemazyre overseas.

Products detail in the report…

Rozlytrek (Entrectinib): Roche

Rozlytrek (Entrectinib, RXDX-101) is an oral medicine for the treatment of locally advanced or metastatic solid tumors that harbor NTRK1/2/3 or ROS1 gene fusions. It is a selective tyrosine kinase inhibitor designed to inhibit the kinase activity of the TRK A/B/C and ROS1 proteins, whose activating fusions drive proliferation in certain types of cancer.

Entrectinib is being investigated across a range of solid tumor types, including breast, cholangiocarcinoma, colorectal, gynecological, neuroendocrine, non-small cell lung, salivary gland, pancreatic, sarcoma, and thyroid cancers. It is approved to treat solid tumors with (NTRK) gene fusion in the US, EU, Canada, and Japan. In addition, it is also approved for metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.

Currently, a phase II clinical trial is undergoing in patients with solid tumors harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK gene rearrangements (fusions). It is approved in the US, EU, and Japan for the treatment of adult and pediatric patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive, advanced, recurrent solid tumors.

Products detail in the report…

Intrahepatic Cholangiocarcinoma (ICCA) Emerging Drugs

Melphalan/HDS: Delcath Systems

Melphalan is a member of the nitrogen mustard alkylating agent family. Delcath Systems is investigating Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) in phase II/III clinical trial for the treatment of intrahepatic cholangiocarcinoma. It is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the US and Europe, it is under investigation for intrahepatic cholangiocarcinoma. It is also being evaluated in a global registration trial for the treatment of patients with ocular melanoma (OM) that has metastasized to the liver (The FOCUS Clinical Trial). In July 2015, the US FDA Office of Orphan Products Development (OOPD) granted Orphan Drug Designation for melphalan to treat cholangiocarcinoma.

Products detail in the report…

Derazantinib: Basilea Pharmaceutica

Derazantinib (BAL087, formerly ARQ 087) is an investigational orally administered small-molecule inhibitor of the FGFR family of kinases with strong activity against FGFR 1, 2, and 3. Therefore, it is called a pan-FGFR kinase inhibitor. In April 2018, Basilea Pharmaceutica in-licensed derazantinib from ArQule. Currently, the product is being evaluated in Phase II for intrahepatic cholangiocarcinoma. Derazantinib has been granted orphan drug designation by the US FDA and European Medicines Agency for advanced intrahepatic cholangiocarcinoma.

Products detail in the report…

Ivosidenib: Agios Pharmaceuticals

Agios Pharmaceuticals is developing Ivosidenib (also known as AG-120), a first-in-class, oral, potent, reversible, targeted inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme. It is a highly targeted investigational medicine for treating patients with cancers that harbor an IDH1 mutation. The company is evaluating the product in late-stage clinical studies for cholangiocarcinoma and IC-Ineligible and eligible frontline acute myeloid leukemia (AML). In November 2016, the FDA granted fast-track designation to ivosidenib (AG-120) for the treatment of patients with previously treated, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation. It was also granted orphan drug designation for ivosidenib for the treatment of cholangiocarcinoma. In March 2018, orphan designation (EU/3/18/1994) was granted by the European Commission to ivosidenib for the treatment of biliary tract cancer. The sponsorship was transferred to Quality Regulatory Clinical Ireland Limited, in August 2018.

Products detail in the report…

List to be continued in the report…

Intrahepatic Cholangiocarcinoma (ICCA) Market Outlook

Intrahepatic cholangiocarcinoma (ICCA) is the type of CCA that forms in the bile ducts inside the liver. The commonly available modalities for the treatment of ICCA include surgery and radiation therapies for curative intent and systemic therapies, including chemotherapy and chemoradiotherapy, for the surgery of ineligible patients.

Surgical resection is the mainstay for the treatment of ICCA. The main goal of the surgery is the hepatic resection with negative margins. Since this type of cancer occurs in the bile ducts inside the liver, surgery may include removing the section or wedge of the liver, and its extent depends on tumor size and location.

Locoregional therapies such as RFA, TACE, DEB-TACE or TACE drug-eluting microspheres, and TARE with yttrium-90 microspheres have shown to be effective in a retrospective analysis of patients with ICCA. Besides these, radiation therapy is also a locoregional treatment option for unresectable ICCA. Fewer patients with ICCA are also given ablation. Although all guidelines recommend radiofrequency ablation (RFA) as a standard treatment for patients with small, early-stage HCC not suitable for surgical therapies, in some cases, patients with ICCA are also treated with RFA.

Since the chances of recurrence are higher in these cancers, the mortality rate becomes higher. The high rates of local and distant recurrence following surgery justify the consideration of adjuvant treatment. As per the NCCN guidelines, the adjuvant treatment for indication include adjuvant capecitabine, gemcitabine monotherapy or combined with cisplatin or capecitabine, capecitabine monotherapy or combined with cisplatin or oxaliplatin, and 5-fluorouracil monotherapy or combined with cisplatin or oxaliplatin.

Additionally, treatment options for advanced BTCs include enrollment in the clinical trial, systemic therapies (gemcitabine or fluoropyrimidine-based chemotherapy, or pembrolizumab for patients with MSI-H/dMMR tumors), fluoropyrimidine-based chemoradiation, and radiotherapy without additional chemotherapy.

There are only a few US FDA approved drugs for the cholangiocarcinoma, i.e. Pemigatinib (Pemazyre) and Entrectinib (Rozlytrek). Pemazyre is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. Rozlytrek is also a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years, and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. It is also the first drug approved in Japan to treat NTRK fusion-positive solid tumors as a tumor agnostic treatment in adult and pediatric patients.

According to DelveInsight, ICCA 7MM is expected to change in the study period 2017-2030.

Key Findings

  • The market size of Intrahepatic Cholangiocarcinoma (ICCA) in the 7MM was USD 99.78 million in 2017.
  • Currently, the market size for early stage ICCA majorly includes surgery with adjuvant chemotherapy and chemoradiation therapy. For the advanced and metastatic stage, systemic chemotherapy is the only option. There is no established second-line systemic therapy following progression after first-line treatment although chemotherapeutic agents either in monotherapy or in combination are used.
  • To meet the increasing demand for the treatment of ICCA, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, and NTRK1, NTRK2 or NTRK3, may increase the market size in the coming years, assisted by an increase in the incident population of ICCA and awareness of the disease.
  • The overall dynamics of ICCA market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Pemazyre (Pemigatinib), Rozlytrek (Entrectinib), Melphalan/HDS, Ivosidenib (AG-120), Infigratinib, Futibatinib (TAS-120), Bintrafusp alfa, Derazantinib, Larotrectinib, E7090, Copanlisib (BAY 80-6946), and Regorafenib.
  • Among the upcoming therapies, Futibatinib (TAS-120) is expected to take the highest market share. It is expected to generate the market size of USD 6.56 million in the launch year, 2024.
  • Out of these emerging therapies, therapies with biomarkers IDH1/IDH2 mutations and FGFR translocations are found to be most promising.
  • Among the 7MM, the United States accounts for the highest market size of ICCA in comparison with EU5 and Japan.

The United States Market Outlook

This section provides the total ICCA market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total ICCA market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total ICCA market size and market size by therapies in Japan are provided.

Intrahepatic Cholangiocarcinoma (ICCA) Drugs Uptake

This section focuses on the rate of uptake of the drugs expected to get launched in the market during the study period 2017-2030. The analysis covers ICCA market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Intrahepatic Cholangiocarcinoma (ICCA) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for ICCA emerging therapies.

Reimbursement Scenario in Intrahepatic Cholangiocarcinoma (ICCA)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the ICCA market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of ICCA, explaining its signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the ICCA epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for ICCA is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the ICCA market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM ICCA market.

Report Highlights:

  • The increasing incidence of the disease along with promising emerging pipeline therapies will positively drive the ICCA market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence ICCA R&D.
  • Major players are involved in developing therapies for ICCA. The launch of emerging therapies will significantly impact the ICCA market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Intrahepatic Cholangiocarcinoma (ICCA) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • ICCA Pipeline Analysis
  • ICCA Market Size and Trends
  • Market Opportunities
  • Impact of Upcoming Therapies

Intrahepatic Cholangiocarcinoma (ICCA) Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • ICCA Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Intrahepatic Cholangiocarcinoma (ICCA) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT Analysis
  • Market Access and Reimbursement 

Key Questions:

Market Insights:

  • What was the ICCA market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the ICCA total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest ICCA market size during the forecast period (2020-2030)?
  • At what CAGR, the ICCA market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the ICCA market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the ICCA market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of ICCA?
  • What is the historical ICCA patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of ICCA at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to ICCA?
  • Out of the above-mentioned countries, which country would have the highest incident population of ICCA during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of ICCA along with the approved therapy?
  • What are the ICCA emerging drugs and their MOA, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of ICCA?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of ICCA?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the ICCA therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for ICCA and their status?
  • What are the key designations that have been granted for the emerging therapies for ICCA?
  • What are the 7MM historical and forecasted market of ICCA?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the ICCA.
  • To understand the future market competition in the ICCA market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for ICCA in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the ICCA market.
  • To understand the future market competition in the ICCA market.

Table of Contents

1 Key Insights

2 Executive Summary of Intrahepatic Cholangiocarcinoma (ICCA)

3 Intrahepatic Cholangiocarcinoma (ICCA) Market Overview at a Glance

  • 3.1 Total Market Share (%) Distribution of ICCA in 2017
  • 3.2 Total Market Share (%) Distribution of ICCA in 2030

4 Intrahepatic cholangiocarcinoma (ICCA): Disease Background and Overview

  • 4.1 Introduction
  • 4.2 Intrahepatic cholangiocarcinoma (ICCA)
  • 4.3 Symptoms of ICCA
  • 4.4 Traditional and new classifications of intrahepatic Cholangiocarcinoma
  • 4.5 Molecular pathogenesis of intrahepatic Cholangiocarcinoma
  • 4.6 Diagnosis of Intrahepatic CCA
    • 4.6.1 Algorithm for the diagnosis of ICCA
    • 4.6.2 Staging of Intrahepatic CCA (ICCA)

5 Patient Journey

6 Epidemiology and Patient Population

  • 6.1 Key Findings
  • 6.2 Epidemiology Methodology
  • 6.3 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the 7MM

7 United States Epidemiology

  • 7.1 Assumptions and Rationale
  • 7.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the United States
  • 7.3 Gender-specific Incident Cases ICCA in the United States
  • 7.4 Age-specific Incident Cases of ICCA in the United States
  • 7.5 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in the United States
  • 7.6 Biomarker-specific Incident Cases of ICCA in the United States

8 EU5 Epidemiology

  • 8.1 Germany Epidemiology
    • 8.1.1 Assumptions and Rationale
    • 8.1.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Germany
    • 8.1.3 Gender-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Germany
    • 8.1.4 Age-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Germany
    • 8.1.5 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Germany
    • 8.1.6 Biomarker-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Germany
  • 8.2 France Epidemiology
    • 8.2.1 Assumptions and rationale
    • 8.2.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in France
    • 8.2.3 Gender-specific Incident Cases of Intrahepatic Cholangiocarcinoma in France
    • 8.2.4 Age-specific Incident Cases of Intrahepatic Cholangiocarcinoma in France
    • 8.2.5 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in France
    • 8.2.6 Biomarker-specific Incident Cases of Intrahepatic Cholangiocarcinoma in France
  • 8.3 Italy Epidemiology
    • 8.3.1 Assumptions and Rationale
    • 8.3.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Italy
    • 8.3.3 Gender-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Italy
    • 8.3.4 Age-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Italy
    • 8.3.5 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Italy
    • 8.3.6 Biomarker-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Italy
  • 8.4 Spain Epidemiology
    • 8.4.1 Assumptions and Rationale
    • 8.4.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Spain
    • 8.4.3 Gender-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Spain
    • 8.4.4 Age-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Spain
    • 8.4.5 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Spain
    • 8.4.6 Biomarker-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Spain
  • 8.5 United Kingdom Epidemiology
    • 8.5.1 Assumptions and Rationale
    • 8.5.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the United Kingdom
    • 8.5.3 Gender-specific Incident Cases of Intrahepatic Cholangiocarcinoma in the United Kingdom
    • 8.5.4 Age-specific Incident Cases of Intrahepatic Cholangiocarcinoma in the United Kingdom
    • 8.5.5 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in the UK
    • 8.5.6 Biomarker-specific Incident Cases of Intrahepatic Cholangiocarcinoma in the United Kingdom

9 Japan Epidemiology

  • 9.1 Assumptions and Rationale
  • 9.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Japan
  • 9.3 Gender-specific Incident Cases of ICCA in Japan
  • 9.1 Age-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Japan
  • 9.2 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Japan
  • 9.3 Biomarker-specific Incident Cases of ICCA in Japan

10 Treatment

  • 10.1 Treatment algorithm for intrahepatic Cholangiocarcinoma
  • 10.2 Guidelines for the treatment of intrahepatic Cholangiocarcinoma
    • 10.2.1 International Liver Cancer Association (ILCA) Guidelines for the Treatment of ICCA
    • 10.2.2 NCCN Clinical Practice Guidelines- Hepatobiliary Cancers (Version 5.2020)

11 Unmet Needs

12 Marketed Drugs

  • 12.1 Pemazyre (Pemigatinib): Incyte Corporation
    • 12.1.1 Drug Description
    • 12.1.2 Regulatory Milestones
    • 12.1.3 Other Developmental Activities
    • 12.1.4 Advantages and Disadvantages
    • 12.1.5 Clinical Development
    • 12.1.6 Safety and Efficacy
    • 12.1.7 Product Profile
  • 12.2 Rozlytrek (Entrectinib): Roche
    • 12.2.1 Product Description
    • 12.2.2 Regulatory Milestones
    • 12.2.3 Other Developmental Activities
    • 12.2.4 Clinical Development
    • 12.2.5 Safety and Efficacy
    • 12.2.6 Product Profile

13 Emerging Therapies

  • 13.1 Key Cross Competition
  • 13.2 Melphalan/HDS: Delcath Systems
    • 13.2.1 Drug Description
    • 13.2.2 Other Developmental Activities
    • 13.2.3 Clinical Development
    • 13.2.4 Safety and Efficacy
    • 13.2.5 Product Profile
  • 13.3 Derazantinib: Basilea Pharmaceutica
    • 13.3.1 Drug Description
    • 13.3.2 Other Developmental Activities
    • 13.3.3 Clinical Development
    • 13.3.4 Safety and Efficacy
    • 13.3.5 Product Profile
  • 13.4 Ivosidenib: Agios Pharmaceuticals
    • 13.4.1 Product Description
    • 13.4.2 Other Developmental Activities
    • 13.4.3 Clinical Development
    • 13.4.4 Safety and Efficacy
    • 13.4.5 Product Profile
  • 13.5 Regorafenib: Bayer
    • 13.5.1 Drug Description
    • 13.5.2 Other Developmental Activities
    • 13.5.3 Clinical Development
    • 13.5.4 Safety and Efficacy
    • 13.5.5 Product Profile
  • 13.6 Larotrectinib: Loxo Oncology/Bayer
    • 13.6.1 Drug Description
    • 13.6.2 Other Developmental Activities
    • 13.6.3 Clinical Development
    • 13.6.4 Safety and Efficacy
    • 13.6.5 Product Profile
  • 13.7 Infigratinib: QED Therapeutics
    • 13.7.1 Drug Description
    • 13.7.2 Other Developmental Activities
    • 13.7.3 Clinical Development
    • 13.7.4 Safety and Efficacy
    • 13.7.5 Product Profile
  • 13.8 Balversa (Erdafitinib): Janssen Pharmaceutical
    • 13.8.1 Product Description
    • 13.8.2 Other Developmental Activities
    • 13.8.3 Clinical Development
    • 13.8.4 Safety and Efficacy
    • 13.8.5 Product Profile
  • 13.9 Futibatinib (TAS-120): Taiho Oncology
    • 13.9.1 Product Description
    • 13.9.2 Other Developmental Activities
    • 13.9.3 Clinical Development
    • 13.9.4 Safety and Efficacy
    • 13.9.5 Product Profile
  • 13.1 Opaganib (ABC294640; Yeliva): RedHill Biopharma
    • 13.10.1 Product Description
    • 13.10.2 Other Developmental Activities
    • 13.10.3 Clinical Development
    • 13.10.4 Safety and Efficacy
    • 13.10.5 Product Profile
  • 13.11 Niraparib (Zejula): GlaxoSmithKline
    • 13.11.1 Product Description
    • 13.11.2 Other Developmental Activities
    • 13.11.3 Clinical Development
    • 13.11.4 Product Profile
  • 13.12 Bintrafusp alfa (GSK4045154; M7824): Merck/GlaxoSmithKline
    • 13.12.1 Product Description
    • 13.12.2 Other Developmental Activities
    • 13.12.3 Clinical Development
    • 13.12.4 Safety and Efficacy
    • 13.12.5 Product Profile
  • 13.13 E7090: Eisai
    • 13.13.1 Product Description
    • 13.13.2 Other Developmental Activities
    • 13.13.3 Clinical Development
    • 13.13.4 Safety and Efficacy
    • 13.13.5 Product Profile
  • 13.14 Lonsurf (Trifluridine and Tipiracil Hydrochloride/TAS-102): Taiho Pharmaceutical/Servier
    • 13.14.1 Product Description
    • 13.14.2 Other Developmental Activities
    • 13.14.3 Clinical Development
    • 13.14.4 Product Profile
  • 13.15 Copanlisib (BAY 80-6946): Bayer
    • 13.15.1 Product Description
    • 13.15.2 Other Developmental Activities
    • 13.15.3 Clinical Development
    • 13.15.4 Safety and Efficacy
    • 13.15.5 Product Profile
  • 13.16 STI-3031 (IMC-001): Sorrento Therapeutics/Yuhan Corporation
    • 13.16.1 Product Description
    • 13.16.2 Other Developmental Activities
    • 13.16.3 Clinical Development
    • 13.16.4 Product Profile
  • 13.17 HMPL-453: Hutchison Medipharma
    • 13.17.1 Drug Description
    • 13.17.2 Other Development Activities
    • 13.17.3 Clinical Development
    • 13.17.4 Product Profile
  • 13.18 Famitinib: Jiangsu HengRui Medicine
    • 13.18.1 Drug Description
    • 13.18.2 Clinical Development
    • 13.18.3 Product Profile
  • 13.19 Durvalumab: AstraZeneca
    • 13.19.1 Drug Description
    • 13.19.2 Other Development Activities
    • 13.19.3 Clinical Development
    • 13.19.4 Safety and Efficacy
    • 13.19.5 Product Profile
  • 13.2 Abemaciclib: Eli Lilly
    • 13.20.1 Drug Description
    • 13.20.2 Other Development Activities
    • 13.20.3 Clinical Development
    • 13.20.4 Product Profile
  • 13.21 Nal-IRI with 5-fluorouracil and/or Leucovorin: Servier Laboratories
    • 13.21.1 Drug Description
    • 13.21.2 Other Development Activities
    • 13.21.3 Clinical Development
    • 13.21.4 Product Profile
  • 13.22 GNS561: Genoscience Pharma
    • 13.22.1 Product Description
    • 13.22.2 Other Developmental Activities
    • 13.22.3 Clinical Development
    • 13.22.4 Safety and Efficacy
    • 13.22.5 Product Profile
  • 13.23 Olutasidenib (FT-2102): Forma Therapeutics
    • 13.23.1 Product Description
    • 13.23.2 Other Developmental Activities
    • 13.23.3 Clinical Development
    • 13.23.4 Safety and Efficacy
    • 13.23.5 Product Profile
  • 13.24 Gemcitabine, Cisplatin, and MEK162: Array BioPharma
    • 13.24.1 Product Description
    • 13.24.2 Other Developmental Activities
    • 13.24.3 Clinical Development
    • 13.24.4 Safety and Efficacy
    • 13.24.5 Product Profile

14 Intrahepatic Cholangiocarcinoma (ICCA): 7MM Market Analysis

  • 14.1 Key Findings
  • 14.1 Market Methodology
  • 14.2 Attribute Analysis
    • 14.2.1 Phase III Drugs
    • 14.2.2 Phase II Drugs
  • 14.3 Market Size of Intrahepatic Cholangiocarcinoma (ICCA) in the 7MM
  • 14.4 Market Size of Intrahepatic Cholangiocarcinoma (ICCA) by therapies in the 7MM
  • 14.5 Intrahepatic Cholangiocarcinoma Market Outlook of the 7MM

15 Potential of Emerging Therapies

16 Key Market Forecast Assumptions

17 United States Market Size

  • 17.1 Total Market size of Intrahepatic Cholangiocarcinoma (ICCA)
  • 17.2 Market Size of Intrahepatic Cholangiocarcinoma (ICCA) by Therapies in the US

18 EU-5 countries: Market Size

  • 18.1 Germany Market Size
    • 18.1.1 Total Market size of Intrahepatic Cholangiocarcinoma (ICCA)
    • 18.1.2 Market Size of ICCA by Therapies in Germany
  • 18.2 France Market Size
    • 18.2.1 Total Market size of Intrahepatic Cholangiocarcinoma (ICCA)
    • 18.2.2 Market Size of Intrahepatic Cholangiocarcinoma (ICCA) by Therapies in France
  • 18.3 Italy Market Size
    • 18.3.1 Total Market size of Intrahepatic Cholangiocarcinoma (ICCA)
    • 18.3.2 Market Size of Intrahepatic Cholangiocarcinoma (ICCA) by Therapies in Italy
  • 18.4 Spain Market Size
    • 18.4.1 Total Market size of Intrahepatic Cholangiocarcinoma (ICCA)
    • 18.4.2 Market Size of Intrahepatic Cholangiocarcinoma (ICCA) by Therapies in Spain
  • 18.5 United Kingdom Market Size
    • 18.5.1 Total Market size of Intrahepatic Cholangiocarcinoma (ICCA)
    • 18.5.2 Market Size of Intrahepatic Cholangiocarcinoma (ICCA) by Therapies in the UK

19 Japan Market Size

  • 19.1 Total Market size of Intrahepatic Cholangiocarcinoma (ICCA)
  • 19.2 Market Size of Intrahepatic Cholangiocarcinoma (ICCA) by Therapies in Japan

20 Market Drivers

21 Market Barriers

22 SWOT Analysis

23 Reimbursement and Market Access

24 Recognized Establishments

25 Appendix

  • 25.1 Report Methodology

26 DelveInsight Capabilities

27 Disclaimer

28 About DelveInsight

Back to Top
전화 문의
F A Q